Ixovex-1
AXP000057.1 · Oncolytic virus
- Platform
- adenovirus (Ad5, E1B splice-variant mutant)
- Originator
- Psivac
- Sponsor
- Psivac
Names
| Name | Type | Source |
|---|---|---|
| Ixovex-1 | preferred name, code | curator, ctgov |
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (Ixovex-1)
- Replication
- conditionally replicating
- Modifications
- E1B splice-variant mutant
- Route
- intratumoral
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT06549946 | Ixovex-1 Single Agent and Combination Therapy | Recruiting | Phase 1/2 | 2024-12-17 | 2027-01-30 | 18 | Head and Neck Cancer; Solid Tumor |
Recent changes
No changes recorded in its trials yet.
Clinical papers
No confirmed clinical papers yet.
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 35596069 | Ixovex-1, a novel oncolytic E1B-mutated adenovirus. | Cancer gene therapy | 2022 | name in title: Ixovex-1 |
Notes
Phase 1/2 NCT06549946, alone and with pembrolizumab. Described by the developer as an E1B-mutant oncolytic adenovirus; exact mutation not confirmed from a primary source.
How to cite
Ixovex-1 (AXP000057.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000057.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.